Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tenofovir Disoproxil Fumarate

FDA-approved product (tablet, oral), marketed as Tenofovir Disoproxil Fumarate, Viread.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tenofovir Disoproxil Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tenofovir Disoproxil Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tenofovir Disoproxil Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)

    NCT00705419 · start 2007-07

    Registered record
    Registry ID
    NCT00705419
    Conditions
    HIV Infections
    Interventions
    Vicriviroc maleate; Vicriviroc maleate; Placebo; Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-07
    Completion
    2010-09
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVicriviroc maleate; Vicriviroc maleate; Placebo; Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
    PhaseNot recorded
    Registry statusCompleted

  • ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

    NCT00335322 · start 2007-02

    Registered record
    Registry ID
    NCT00335322
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2011-11
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    InterventionTruvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    PhasePhase 4
    Registry statusCompleted

  • A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

    NCT00110305 · start 2005-06

    Registered record
    Registry ID
    NCT00110305
    Conditions
    Human Immunodeficiency Virus Type 1
    Interventions
    TMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz; Non-nucleoside reverse transcriptase inhibitor (NRTIs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-06
    Completion
    2011-12
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1
    InterventionTMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz +1 more
    PhasePhase 2
    Registry statusCompleted

  • Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

    NCT00087464

    Registered record
    Registry ID
    NCT00087464
    Conditions
    HIV Infections
    Interventions
    Emtricitabine; Nevirapine; Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmtricitabine; Nevirapine; Tenofovir disoproxil fumarate
    PhaseNot applicable
    Registry statusWithdrawn

  • Replicor Compassionate Access Program

    NCT05683548

    Registered record
    Registry ID
    NCT05683548
    Conditions
    Viral Hepatitis B; Viral Hepatitis D; Cirrhosis, Liver; Decompensated Cirrhosis; Ascites Hepatic; Varices, Esophageal; Hepatocellular Carcinoma
    Interventions
    REP 2139-Mg; Tenofovir Disoproxil Fumarate; Pegylated interferon alpha2a
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionViral Hepatitis B; Viral Hepatitis D; Cirrhosis, Liver; Decompensated Cirrhosis +3 more
    InterventionREP 2139-Mg; Tenofovir Disoproxil Fumarate; Pegylated interferon alpha2a
    PhaseNot recorded
    Registry statusNo longer available